- Latest available (Revised)
- Point in Time (31/12/2020)
- Original (As made)
Point in time view as at 31/12/2020. This version of this part contains provisions that are prospective.
The term provision is used to describe a definable element in a piece of legislation that has legislative effect – such as a Part, Chapter or section. A version of a provision is prospective either:
Commencement Orders listed in the ‘Changes to Legislation’ box as not yet applied may bring this prospective version into force.
There are currently no known outstanding effects for the The Patents (Amendment) (EU Exit) Regulations 2019, PART 8.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
51. Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products is amended as follows.
Commencement Information
I1Reg. 51 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1
52.—(1) Article 1 (interpretation) is amended as follows.
(2) In paragraph (e) for “Article 36 of Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use”, substitute “ regulation 58A(3) of the Human Medicines Regulations 2012 M1 ”.
(3) After paragraph (e) insert—
“(f)‘comptroller’ means the Comptroller-General of Patents, Designs and Trade Marks;
[F1(g) ‘court’ means—
(i)as respects England and Wales, the High Court;
(ii)as respects Scotland, the Court of Session;
(iii)as respects Northern Ireland, the High Court in Northern Ireland;]
(h)“EEA authorisation” means an authorisation to place a medicinal product on the market which has effect in an EEA state in accordance with Directive 2001/83/EC or Directive 2001/82/EC;
(i)‘patent’ means a patent which has effect in the United Kingdom;
(j)‘UK authorisation’ means, in relation to a product, an authorisation to place that product on the market [F2in the United Kingdom] as a medicinal product granted [F3or having effect as if granted] in accordance with—
(i)Part 5 of the Human Medicines Regulations 2012; or
(ii)regulation 4(3) of, and Schedule 1 to, the Veterinary Medicines Regulations 2013 M2.”.
Textual Amendments
F1Words in reg. 52(3) substituted (31.12.2020 immediately before IP completion day) by The Intellectual Property (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1050), regs. 1(2), 34(a)
F2Words in reg. 52(3) inserted (31.12.2020 immediately before IP completion day) by The Supplementary Protection Certificates (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1471), regs. 1(2), 3(3) (with reg. 7)
F3Words in reg. 52(3) inserted (31.12.2020 immediately before IP completion day) by The Intellectual Property (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1050), regs. 1(2), 34(b)
Commencement Information
I2Reg. 52 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1
Marginal Citations
M1S.I. 2012/1916. Regulation 58A is inserted by S.I. 2019/775, reg. 64.
Prospective
F453. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Textual Amendments
F4Reg. 53 omitted (31.12.2020 immediately before IP completion day) by virtue of The Intellectual Property (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1050), regs. 1(2), 35
54. For Articles 2 (scope) and 3 (conditions for obtaining a certificate), substitute—
A product may, under the terms and conditions provided for in this Regulation, be the subject of a certificate if it is—
(a)protected by a patent; and
(b)the subject of a UK [F5, GB or NI] authorisation prior to being placed on the market as a medicinal product.
Where an application is submitted under Article 7, a certificate shall be granted if, at the date of submission of that application—
(a)the product is protected by a basic patent in force;
(b)there is a valid UK [F6, GB or NI] authorisation to place the product on the market;
(c)the product has not already been the subject of a certificate;
(d)the authorisation referred to in point (b) is the first UK [F7, GB or NI] authorisation to place the product on the market as a medicinal product [F8in the territory of the United Kingdom, the territory of England and Wales and Scotland or the territory of Northern Ireland as the case may be].”.
Textual Amendments
F5Words in reg. 54 inserted (31.12.2020 immediately before IP completion day) by The Supplementary Protection Certificates (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1471), regs. 1(2), 3(4) (with reg. 7)
F6Words in reg. 54 inserted (31.12.2020 immediately before IP completion day) by The Supplementary Protection Certificates (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1471), regs. 1(2), 3(5)(a) (with reg. 7)
F7Words in reg. 54 inserted (31.12.2020 immediately before IP completion day) by The Supplementary Protection Certificates (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1471), regs. 1(2), 3(5)(b)(i) (with reg. 7)
F8Words in reg. 54 inserted (31.12.2020 immediately before IP completion day) by The Supplementary Protection Certificates (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1471), regs. 1(2), 3(5)(b)(ii) (with reg. 7)
Commencement Information
I3Reg. 54 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1
55.—(1) Article 8 (content of application for a certificate) is amended as follows.
(2) For paragraph 1(a)(iv), substitute—
[F9“(iv) the number and date of the UK, GB or NI authorisation, or where there is more than one such authorisation, of each authorisation as referred to in Article 3(b) and (d);]
(v)the number and date of the earliest of any EEA authorisation, the granting of which predates the granting of the UK [F10, GB or NI] authorisation [F11as referred to in Article 3(b) and (d)];”.
(3) For paragraph 1(b) and (c), substitute—
“(b)a copy of the UK [F12, GB or NI authorisation or, where there is more than one such authorisation, of each] authorisation to place the product on the market, as referred to in Article 3(b) [F13and (d)], in which the product is identified, containing in particular the number and date of the authorisation and the summary of the product characteristics listed in Article 11 of Directive 2001/83/EC, Article 14 of Directive 2001/82/EC, Part 2 to Schedule 8 of the Human Medicines Regulations 2012 or Part 1 of Schedule 1 to the Veterinary Medicines Regulations 2013;
(c)where the product is the subject of one or more EEA authorisations granted prior to the UK [F14, GB or NI] authorisation referred to in Article 3(b) [F15and (d)], the applicant must provide in relation to the earliest of any such EEA authorisations—
(i)information regarding the identity of the product thus authorised;
(ii)information regarding the legal provision under which the authorisation procedure took place; and
(iii)a copy of the notice publishing the authorisation in the appropriate official publication;”.
(4) In paragraph 1(d)—
(a)in paragraph (i), for “Article 36(1) of Regulation (EC) No 1901/2006” substitute “ regulation 58A(2)(a) of the Human Medicines Regulations 2012 ”; and
(b)omit paragraph (ii).
(5) Omit paragraph (4).
Textual Amendments
F9Words in reg. 55(2) substituted (31.12.2020 immediately before IP completion day) by The Supplementary Protection Certificates (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1471), regs. 1(2), 3(6)(a) (with reg. 7)
F10Words in reg. 55(2) inserted (31.12.2020 immediately before IP completion day) by The Supplementary Protection Certificates (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1471), regs. 1(2), 3(6)(b)(i) (with reg. 7)
F11Words in reg. 55(2) inserted (31.12.2020 immediately before IP completion day) by The Supplementary Protection Certificates (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1471), regs. 1(2), 3(6)(b)(ii) (with reg. 7)
F12Words in reg. 55(3) inserted (31.12.2020 immediately before IP completion day) by The Supplementary Protection Certificates (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1471), regs. 1(2), 3(7)(a)(i) (with reg. 7)
F13Words in reg. 55(3) inserted (31.12.2020 immediately before IP completion day) by The Supplementary Protection Certificates (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1471), regs. 1(2), 3(7)(a)(ii) (with reg. 7)
F14Words in reg. 55(3) inserted (31.12.2020 immediately before IP completion day) by The Supplementary Protection Certificates (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1471), regs. 1(2), 3(7)(b)(i) (with reg. 7)
F15Words in reg. 55(3) inserted (31.12.2020 immediately before IP completion day) by The Supplementary Protection Certificates (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1471), regs. 1(2), 3(7)(b)(ii) (with reg. 7)
Commencement Information
I4Reg. 55 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1
56.—(1) Article 9 (lodging of an application for a certificate) is amended as follows.
(2) For paragraph 1 substitute—
“1. An application for a certificate (or an extension of the duration of a certificate) shall be lodged with the comptroller.”.
(3) In the introductory words of paragraph 2, for “the authority referred to in paragraph 1”, substitute “ the comptroller ”.
(4) For sub-paragraphs (d) and (e) of paragraph 2, substitute—
[F16“(d) the number and date of the UK, GB or NI authorisation or, where there is more than one such authorisation, each authorisation provided under Article 8(1)(b), the product identified in the authorisation or each authorisation and the territory in respect of which the authorisation has been granted or has effect as if granted];
(e)where there are authorisations granted in the EEA before [F17any UK, GB or NI authorisation provided under Article 8(1)(b)], the number and date of the earliest EEA authorisation;”.
Textual Amendments
F16Words in reg. 56(4) substituted (31.12.2020 immediately before IP completion day) by The Supplementary Protection Certificates (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1471), regs. 1(2), 3(8)(a) (with reg. 7)
F17Words in reg. 56(4) substituted (31.12.2020 immediately before IP completion day) by The Supplementary Protection Certificates (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1471), regs. 1(2), 3(8)(b) (with reg. 7)
Commencement Information
I5Reg. 56 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1
57.—(1) Article 10 (grant of the certificate or rejection of the application for a certificate) is amended as follows.
(2) In paragraphs 1 to 3, for “the authority referred to in Article 9(1)”, substitute “ the comptroller ”.
(3) In paragraph 2, after “in this Regulation”, insert “ or any prescribed fee is not paid ”.
(4) In paragraph 3, after “Article 8”, insert “ or the prescribed fee relating to the application has not been paid ”.
(5) In paragraph 4, for “the authority”, substitute “ the comptroller ”.
(6) Omit paragraph 5.
(7) After paragraph 6, insert—
F18“7. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .”.
Textual Amendments
F18Words in reg. 57(7) omitted (31.12.2020 immediately before IP completion day) by virtue of The Supplementary Protection Certificates (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1471), regs. 1(2), 3(9) (with reg. 7)
Commencement Information
I6Reg. 57 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1
58.—(1) Article 11 (publication) is amended as follows.
(2) In paragraphs 1 and 2, for “the authority referred to in Article 9(1)” substitute “ the comptroller ”.
(3) In paragraph 1—
(a)[F19for paragraph (d), insert—
“(d)the number and date of the UK, GB or NI authorisation or, where there is more than one such authorisation, of each authorisation provided under Article 8(1)(b) or Article 13A(1), the product identified in the authorisation and the territory in respect of which the authorisation has been granted or has effect as if granted;”];
(b)for sub-paragraph (e), substitute—
“(e)where there are EEA authorisations granted before [F20any UK, GB or NI authorisation provided under Article 8(1)(b)], the number and date of the earliest EEA authorisation;”.
Textual Amendments
F19Words in reg. 58(3)(a) substituted (31.12.2020 immediately before IP completion day) by virtue of The Supplementary Protection Certificates (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1471), regs. 1(2), 3(10)(a) (with reg. 7)
F20Words in reg. 58(3)(b) substituted (31.12.2020) by The Supplementary Protection Certificates (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1471), regs. 1(2), 3(10)(b) (with reg. 7)
Commencement Information
I7Reg. 58 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1
59. Omit Article 12 (annual fees).
Commencement Information
I8Reg. 59 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1
60.—(1) Article 13 (duration of the certificate) is amended as follows.
(2) In paragraph 1, for “the Community”, substitute “ the area comprising the European Economic Area and the United Kingdom ”.
(3) In paragraph 3, for “Article 36 of Regulation (EC) No 1901/2006”, substitute “ regulation 58A of the Human Medicines Regulations 2012 ”.
Commencement Information
I9Reg. 60 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1
61.—(1) Article 14 (expiry of the certificate) is amended as follows.
(2) The existing text is numbered as paragraph 1.
(3) For sub-paragraphs (c) and (d) of the renumbered paragraph 1, substitute—
“(c)if the prescribed annual fee is not paid in time; [F21or]
(d)if and as long as the product covered by the certificate may no longer be placed on the market following the withdrawal of [F22all UK, GB and NI] authorisations to place on the market. The comptroller may decide on the lapse of the certificate either of the comptroller's own motion or at the request of a third party.”.
F23(4) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Textual Amendments
F21Word in reg. 61(3) inserted (31.12.2020 immediately before IP completion day) by The Supplementary Protection Certificates (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1471), regs. 1(2), 3(11)(a) (with reg. 7)
F22Words in reg. 61(3) substituted (31.12.2020 immediately before IP completion day) by The Supplementary Protection Certificates (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1471), regs. 1(2), 3(11)(b) (with reg. 7)
F23Reg. 61(4) omitted (31.12.2020 immediately before IP completion day) by virtue of The Supplementary Protection Certificates (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1471), regs. 1(2), 3(12) (with reg. 7)
Commencement Information
I10Reg. 61 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1
62. In paragraph 2 of Article 15 (invalidity of the certificate), for “F24... the body responsible under national law for the revocation of the corresponding basic patent” substitute “ the comptroller or the court ”.
Textual Amendments
F24Word in reg. 62 omitted (31.12.2020 immediately before IP completion day) by virtue of The Intellectual Property (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1050), regs. 1(2), 36
Commencement Information
I11Reg. 62 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1
63.—(1) Article 16 (revocation of an extension of the duration) is amended as follows.
(2) In paragraph 1, for “Article 36 of Regulation (EC) No 1901/2006”, substitute “ regulation 58A(3) of the Human Medicines Regulations 2012 ”.
(3) In paragraph 2, for “the body responsible under national law for the revocation of the corresponding basic patent”, substitute “ the comptroller or the court ”.
Commencement Information
I12Reg. 63 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1
64. For references in Article 17 (notification of lapse or invalidity) to “the authority referred to in Article 9(1)”, substitute “ the comptroller ”.
Commencement Information
I13Reg. 64 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1
65. Omit Article 18 (appeals).
Commencement Information
I14Reg. 65 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1
66. For paragraph 1 of Article 19 (procedure), substitute—
“1. In the absence of procedural provisions in this Regulation, the procedural provisions applicable to the corresponding basic patent (as modified by section 128B of, and Schedule 4A to, the Patents Act 1977) shall apply to the certificate.”.
Commencement Information
I15Reg. 66 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1
67. Omit Articles 20 (enlargement of the Community) and 21 (transitional provisions).
Commencement Information
I16Reg. 67 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1
68. After Article 23 (entry into force), omit “This Regulation shall be binding in its entirety and directly applicable in all Member States.”
Commencement Information
I17Reg. 68 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1
69.—(1) This regulation applies to—
(a)An application for an extension of the duration of a certificate, filed in accordance with Article 7 but not determined before [F25IP completion day]; and
(b)An extension of the duration of a certificate granted—
(i)before [F25IP completion day]; or
(ii)after [F25IP completion day], pursuant to an application falling within sub-paragraph (a);
(2) Where this regulation applies, Articles 1(e), 8(1)(d), 13(3), and 16(1) of Regulation 469/2009 continue to apply without the amendments made by these Regulations.
(3) Where paragraph (1) applies—
(a)Article 8(1)(d)(ii) is to be read as if, for the words “all other Member States”, there were substituted “ all Member States ”;
(b)Articles 13(3) and 16(1) are to be read as if, for the words “all Member States” in Article 36(3) of Regulation 1901/2006, there were substituted “ the United Kingdom and all Member States ”.
Textual Amendments
F25Words in reg. 69 substituted (31.12.2020 immediately before IP completion day) by The Intellectual Property (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1050), regs. 1(2), 37
Commencement Information
I18Reg. 69 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: